Substantial research is dedicated to the role of autoantigens for the elevation of immunologic tolerance as an alternative immune modifying therapy compared with immunosuppression in T1D, with primary antigen GAD65 being a predominant therapeutic target (Baekkeskov et al, 1982; Harrison, 2005). The gene discussed is GAD2; the disease is type 1 diabetes mellitus.